Setrusumab is a Monoclonal Antibody owned by Mereo Biopharma Group, and is involved in 6 clinical trials, of which 4 were completed, 1 is ongoing, and 1 is planned.
Setrusumab is an anti-sclerostin monoclonal antibody. Sclerostin is a protein, an inhibitor of osteoblastogenesis. It is a glycoprotein secreted by osteocytes. Sclerostin after secretion by osteocytes travels through osteocyte canaliculi to the bone surface where it binds to coreceptors LRP5 and LRP6. It prevents localization with frizzled protein and Wnt signaling, and thereby reducing osteoblastogenesis and bone formation.
The revenue for Setrusumab is expected to reach a total of $803m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Setrusumab NPV Report.
Setrusumab was originated by Novartis and MorphoSys and is currently owned by Mereo Biopharma Group. Ultragenyx Pharmaceutical is the other company associated in development or marketing of Setrusumab.
Setrusumab is under development for the treatment of osteogenesis imperfecta type I, III and IV (also known as Brittle bone syndrome). The drug candidate is administered intravenously through infusion. It is a fully humanized monoclonal antibody targeting sclerostin. It was also under development for hypophosphatasia (HPP), osteoporosis in postmenopausal women and chronic kidney disease.
Ultragenyx Pharmaceutical Overview
Ultragenyx Pharmaceutical (Ultragenyx) develops novel medicines for rare and ultra-rare genetic diseases. It has three marketed products, Mepsevii (vestronidase alfa) for the treatment of Mucopolysaccharidosis (Sly syndrome); Dojolvi (triheptanoin), a highly purified, synthetic, 7-carbon fatty acid triglyceride for long-chain fatty acid oxidation disorders (LC-FAOD) and Crysvita (burosumab), a fully human monoclonal antibody for the treatment of X-linked hypophosphatemia (XLH). Its pipeline includes DTX401 for the treatment of glycogen storage disease type Ia, or GSDIa; UX701 for Wilson disease; UX053 for glycogen storage disease type III; and GTX-102 for Angelman syndrome in partnership with GeneTx. It works in partnership with various academic institutes and biotechnology companies to advance its product candidates. Ultragenyx is headquartered in Novato, California, the US.
The company reported revenues of (US Dollars) US$351.4 million for the fiscal year ended December 2021 (FY2021), an increase of 29.7% over FY2020. The operating loss of the company was US$381.7 million in FY2021, compared to an operating loss of US$330.1 million in FY2020. The net loss of the company was US$454 million in FY2021, compared to a net loss of US$186.6 million in FY2020. The company reported revenues of US$90.7 million for the third quarter ended September 2022, an increase of 1.5% over the previous quarter.
Quick View – Setrusumab
|Highest Development Stage|